Skip to main content
Erschienen in: Supportive Care in Cancer 7/2005

01.07.2005 | Short Communication

Review of telephone follow-up experience at the Rapid Response Radiotherapy Program

verfasst von: Edward Chow, Kin-Wah Fung, Nicole Bradley, Lori Davis, Lori Holden, Cyril Danjoux

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To review the feasibility of telephone follow-up following a 3-year experience from 1999 to 2001 at the Rapid Response Radiotherapy Program as a prospective radiotherapy outcome assessment of symptom palliation.

Methods and materials

Patients referred for palliative radiotherapy for symptom control from 1999 to 2001 were asked to rate symptom distress using the Edmonton Symptom Assessment System (ESAS) at initial consultation. Patient demographics and analgesic consumption were recorded. Telephone follow-up interviews were conducted with all patients who received radiotherapy during weeks 1, 2, 4, 8, and 12 after radiotherapy using the ESAS and an analgesic diary. Clinic follow-up visits were conducted only if necessary.

Results

Between January 1999 and December 2001, 830 patients received palliative radiotherapy. Of these patients, 260 (31.3%) died during the 12-week follow-up period. The percentage of surviving patients responding to the telephone interview ranged from 48.2% (week 12) to 56.6% (week 4) during the 12-week study.

Conclusion

Telephone follow-up is a feasible tool for prospective outcome assessment of symptom palliation in metastatic cancer patients. Telephone follow-up is recommended for outcome assessment of symptom relief when it can achieve the same purpose as clinic follow-up. Data collection remains a challenge in the palliative patient population. Further studies are required to determine how well other methods of maximizing data collection, such as through the use of caregivers, can provide reliable and accurate information.
Literatur
1.
Zurück zum Zitat Chow E, Wong R, Connolly R, Hruby G, Franssen E, Fung KW, et al (2001) Prospective assessment of symptom palliation for patients attending a Rapid Response Radiotherapy Program—feasibility of telephone follow-up. J Pain Symptom Manage 22:649–656CrossRefPubMed Chow E, Wong R, Connolly R, Hruby G, Franssen E, Fung KW, et al (2001) Prospective assessment of symptom palliation for patients attending a Rapid Response Radiotherapy Program—feasibility of telephone follow-up. J Pain Symptom Manage 22:649–656CrossRefPubMed
2.
Zurück zum Zitat Bruera E, Kuehn N, Miller M, Selmser P, MacMillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller M, Selmser P, MacMillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
3.
Zurück zum Zitat Haddad P, Wilson P, Wong R, Williams D, Sharma N, Soban F, et al (2003) The success of data collection in the palliative setting—telephone or clinic follow-up? Support Care Cancer 11:555–559CrossRefPubMed Haddad P, Wilson P, Wong R, Williams D, Sharma N, Soban F, et al (2003) The success of data collection in the palliative setting—telephone or clinic follow-up? Support Care Cancer 11:555–559CrossRefPubMed
4.
Zurück zum Zitat Chow E, Wu J, Hoskin P, Coia L, Bentzen S, Blitzer P, on behalf of the International Bone Metastases Consensus Working Party (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280CrossRefPubMed Chow E, Wu J, Hoskin P, Coia L, Bentzen S, Blitzer P, on behalf of the International Bone Metastases Consensus Working Party (2002) International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 64:275–280CrossRefPubMed
5.
Zurück zum Zitat Bruera E, Michaud M, Vigano A, Neumann CM, Watanabe S, Hanson J (2001) Multidisciplinary symptom control clinic in a cancer centre: a retrospective study. Support Care Cancer 9:162–168CrossRefPubMed Bruera E, Michaud M, Vigano A, Neumann CM, Watanabe S, Hanson J (2001) Multidisciplinary symptom control clinic in a cancer centre: a retrospective study. Support Care Cancer 9:162–168CrossRefPubMed
6.
Zurück zum Zitat Sardell S, Sharpe G, Ashley S, Guerrero D, Brada M (2000) Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol 12:36–41 Sardell S, Sharpe G, Ashley S, Guerrero D, Brada M (2000) Evaluation of a nurse-led telephone clinic in the follow-up of patients with malignant glioma. Clin Oncol 12:36–41
Metadaten
Titel
Review of telephone follow-up experience at the Rapid Response Radiotherapy Program
verfasst von
Edward Chow
Kin-Wah Fung
Nicole Bradley
Lori Davis
Lori Holden
Cyril Danjoux
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-004-0707-1

Weitere Artikel der Ausgabe 7/2005

Supportive Care in Cancer 7/2005 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.